DrugNews Update: Merck Files Challenge Over Plans For Generic NuvaRing
Chicago, IL (PRWEB) January 11, 2014 -- The birth control resource center at DrugNews.net has added new information for those patients using the contraceptive NuvaRing. The maker of the device, Merck, recently challenged another company’s plans to market a generic version in upcoming years*.
DrugNews is a patient resource center offering the latest news, safety alerts, product recalls and litigation updates on popular prescription drugs. Visitors can see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.
NuvaRing is a small plastic contraceptive insert approved by the FDA for sale in the United States in 2001. Today it is marketed in over 50 countries and used by an estimated 1.5 million people worldwide**.
DrugNews has uncovered health warnings from experts such as the New England Journal of Medicine showing vaginal ring contraceptives like NuvaRing may result in a 6.5 times increased risk of blood clots***.
Now, The resource center has learned NuvaRing maker Merck has filed suit against rival drug company Actavis over allegations that it marketed plans to release a generic version of NuvaRing prior to the expiration of Merck’s patent in 2018*.
According to court records, a number of women have already filed a NuvaRing lawsuit against Merck alleging blood clots from the device, with cases consolidated to a special federal multidistrict litigation court. The formal case is In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri. The latest court records show 1,610 cases filed as of December 16****.
Anyone who suffered a blood clot, stroke, DVT or pulmonary embolism after using NuvaRing is urged to visit DrugNews or speak with a lawyer about their legal rights as soon as possible. DrugNews only recommends lawyers who have already handled NuvaRing lawsuits.
For more information on the research, side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit http://www.DrugNews.net.
*Bloomberg, 12/24/13; bloomberg.com/news/2013-12-24/merck-sues-actavis-unit-over-patent-for-generic-nuvaring.html; Merck Sharp & Dohme BV v. Warner Chilcott Co., U.S. District Court, District of Delaware (Wilmington).
**Huffington Post, 12/18/13; huffingtonpost.com/2013/12/18/nuvaring-blood-clots_n_4461429.html
***New England Journal of Medicine, 6/14/12; nejm.org/doi/full/10.1056/NEJMoa1111840
****Judicial Panel on Multidistrict Litigation, 12/16/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-December-16-2013.pdf
Chris Schroeder, DrugNews, http://www.DrugNews.net, +1 888-987-4866, [email protected]
Share this article